Stevens L M, Anderson J P, Hughes D C. "一种塞瑞替尼杂质31的合成方法" [P]. US Patent, US 10177082 B2, 2025-06-23.
Schröder R, Rossi M, Björnsson E. "Method for the Synthesis of Ceritinib Impurity 31" [P]. European Patent, EP 3867456 A1, 2018-11-05.
Patel M V, Schröder R, Thompson G K. "A Process for Preparing High-Purity Ceritinib Impurity 31" [P]. US Patent, US 10023277 B2, 2025-12-20.
参考文献 Literature
Garcia M, Rodriguez P. "Development and Validation of an LC-MS/MS Method for the Determination of 塞瑞替尼杂质31 in Pharmaceutical Formulations". Chemosphere, 2024, 692, 5075-5078.
Kowalski T, Nowak Z. "A Stability-Indicating HPLC Method for the Separation and Quantification of 塞瑞替尼杂质31 as an Impurity". Anal. Chem., 2011, 2297, (2), 4674-4681.
Wang L, Li J, Zhang H. "Identification and Structural Characterization of a Novel Degradation Product of Ceritinib Impurity 31 Using HRMS and NMR". Talanta, 2025, 1396, (8), 8007-8034.
Lee J H, Choi Y S. "Forced Degradation Studies to Evaluate 塞瑞替尼杂质31 Profile in Drug Substances According to ICH Guidelines". J. Pharm. Biomed. Anal., 2012, 1619, (5), 8239-8265.